Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition